Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2006;55:287–303. doi: 10.1007/3-540-30822-9_16

New Therapeutics Targets in Chronic Viral Cardiomyopathy

W Poller 4, H Fechner 4, U Kühl 4, M Pauschinger 4, H -P Schultheiss 4
Editors: H -P Schultheiss1, J -F Kapp2, G Grötzbach3
PMCID: PMC7123174  PMID: 16329668

Abstract

Dilated cardiomyopathy (DCM) is a prevalent heart muscle disease characterized by impaired contractility and dilation of the ventricles. Recent clinical research suggests that cardiotropic viruses are important environmental pathogenic factors in human DCM, which may therefore be considered as a chronic viral cardiomyopathy. All virus-positive DCM patients thus come into the focus of virological research and should be considered for antiviral strategies. Interferon-β therapy has been shown to mediate virus elimination in patients with adenovirus or coxsackievirus persistence.We discuss here several possible new molecular targets for patients infected with cardiotropic viruses in (1) the cellular virus uptake system, (2) virus-induced cellular signaling pathways, and (3) interactions between virus-encoded proteins with important cellular target proteins. The potential of these approaches in the setting of a chronic viral infection is significantly different from that in an acute viral infection. Specific problems encountered in a chronic situation and possible solutions are discussed.

Keywords: Dilate Cardiomyopathy, Innate Immune Signaling, CVB3 Infection, Experimental Autoimmune Myocarditis, Lymphocytic Myocarditis

Contributor Information

H. -P. Schultheiss, Email: heinz-peter.Schultheiss@charite.de

J. -F. Kapp, Email: joachim-friedrich.kapp@schering.de

G. Grötzbach, Email: georg.groetzbach@schering.de

W. Poller, Email: wolfgang.poller@charite.de

U. Kühl, Email: uwe.kuehl@charite.de

M. Pauschinger, Email: matthias.pauschinger@charite.de

H. -P. Schultheiss, Email: heinz-peter.Schultheiss@charite.de

References

  1. Baboonian C., Davies M., Booth J., McKenna W. Coxsackie B viruses and human heart disease. Curr Top Microbiol Immunol. 1997;223:31–52. doi: 10.1007/978-3-642-60687-8_3. [DOI] [PubMed] [Google Scholar]
  2. Badorff C., Lee G., Lamphear B., et al. Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med. 1999;5:320–326. doi: 10.1038/6543. [DOI] [PubMed] [Google Scholar]
  3. Bergelson J., Cunningham J., Droguett G., et al. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science. 1997;275:1320–1323. doi: 10.1126/science.275.5304.1320. [DOI] [PubMed] [Google Scholar]
  4. Bhuyan P.K., Kariko K., Capodici J., et al. Short interfering RNA-mediated inhibition of herpes simplex virus type 1 gene expression and function during infection of human keratinocytes. J Virol. 2004;78:10276–10281. doi: 10.1128/JVI.78.19.10276-10281.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bowles N., Richardson P., Olsen E., Archard L. Detection of coxsackie-B virus-specific RNA sequences in myocardial biopsy samples from patients with myocarditis and dilated cardiomyopathy. Lancet. 1986;1:1120–1123. doi: 10.1016/S0140-6736(86)91837-4. [DOI] [PubMed] [Google Scholar]
  6. Chien K. Genotype, phenotype: upstairs, downstairs in the family of cardiomyopathies. J Clin Invest. 2003;111:175–178. doi: 10.1172/JCI200317612. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Dave R.S., Pomerantz R.J. Antiviral effects of human immunodeficiency virus type 1-specific small interfering RNAs against targets conserved in select neurotropic viral strains. J Virol. 2004;78:13687–13696. doi: 10.1128/JVI.78.24.13687-13696.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Deonarain R., Cerullo D., Fuse K., Liu P.P., Fish E.N. Protective role for interferon-beta in coxsackievirus B3 infection. Circulation. 2004;110:3540–3543. doi: 10.1161/01.CIR.0000136824.73458.20. [DOI] [PubMed] [Google Scholar]
  9. Dörner A., Xiong D., Couch K., Yajima T., Knowlton K. Alternatively spliced soluble Coxsackie-adenovirus receptors inhibit Coxsackievirus infection. J Biol Chem. 2004;279:18497–18503. doi: 10.1074/jbc.M311754200. [DOI] [PubMed] [Google Scholar]
  10. Fechner H., Noutsias M., Tschoepe C., et al. Induction of coxsackievirus-adenovirus-receptor expression during myocardial tissue formation and remodeling — identification of a cell-cell contact dependent regulatory mechanism. Circulation. 2003;107:876–882. doi: 10.1161/01.CIR.0000050150.27478.C5. [DOI] [PubMed] [Google Scholar]
  11. Franz W., Muller O., Katus H. Cardiomyopathies: from genetics to the prospect of treatment. Lancet. 2001;358:1627–1637. doi: 10.1016/S0140-6736(01)06657-0. [DOI] [PubMed] [Google Scholar]
  12. Frustaci A., Chimenti C., Calabrese F., Pieroni M., Thiene G., Maseri A. Immunosuppressive therapy for active lymphocytic myocarditis: virologic and immunologic profile of responders versus non-responders. Circulation. 2003;107:857–863. doi: 10.1161/01.CIR.0000048147.15962.31. [DOI] [PubMed] [Google Scholar]
  13. Gaggar A., Shayakhmetov D., Lieber A. CD46 is a cellular receptor for group B adenoviruses. Nat Med. 2003;9:1408–1412. doi: 10.1038/nm952. [DOI] [PubMed] [Google Scholar]
  14. Gao X., Wang H., Sairenji T. Inhibition of Epstein-Barr virus (EBV) reactivation by short interfering RNAs targeting p38 mitogen-activated protein kinase or c-myc in EBV-positive epithelial cells. J Virol. 2004;78:11798–11806. doi: 10.1128/JVI.78.21.11798-11806.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Grimm D., Pandey K., Kay M.A. Adeno-associated virus vectors for short hairpin RNA expression. Methods Enzymol. 2005;392:381–405. doi: 10.1016/S0076-6879(04)92023-X. [DOI] [PubMed] [Google Scholar]
  16. Hertzog P., O’Neill L., Hamilton J. The interferon in TLR signaling: more than just antiviral. Trends Immunol. 2003;24:534–539. doi: 10.1016/j.it.2003.08.006. [DOI] [PubMed] [Google Scholar]
  17. Kameoka M., Nukuzuma S., Itaya A., et al. RNA interference directed against Poly(ADP-Ribose) polymerase 1 efficiently suppresses human immunodeficiency virus type 1 replication in human cells. J Virol. 2004;78:8931–8934. doi: 10.1128/JVI.78.16.8931-8934.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Kühl U., Pauschinger M., Schwimmbeck P., et al. Interferon-β treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation. 2003;107:2793–2798. doi: 10.1161/01.CIR.0000072766.67150.51. [DOI] [PubMed] [Google Scholar]
  19. Kühl U., Pauschinger M., Bock T., et al. Parvovirus B19 infection mimicking acute myocardial infarction. Circulation. 2003;108:945–950. doi: 10.1161/01.CIR.0000085168.02782.2C. [DOI] [PubMed] [Google Scholar]
  20. Kühl U., Pauschinger M., Noutsias M., Seeberg B., Bock T., Lassner D., Poller W., Kandolf R., Schultheiss H.P. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with “idiopathic” left ventricular dysfunction. Circulation. 2005;111:887–893. doi: 10.1161/01.CIR.0000155616.07901.35. [DOI] [PubMed] [Google Scholar]
  21. Li G., Li X.P., Peng Y., Liu X., Li X.H. Effect of inhibition of EBV-encoded latent membrane protein-1 by small interfering RNA on EBV-positive nasopharyngeal carcinoma cell growth. Di Yi Jun Yi Da Xue Xue Bao. 2004;24:241–246. [PubMed] [Google Scholar]
  22. Liu P., Aitken K., Kong Y.Y., Opavsky M.A., Martino T., Dawood F., Wen W.H., Kozieradzki I., Bachmaier K., Straus D., Mak T.W., Penninger J.M. The tyrosine kinase p56lck is essential in coxsackievirus B3-mediated heart disease. Nat Med. 2000;6:429–434. doi: 10.1038/74689. [DOI] [PubMed] [Google Scholar]
  23. Lu A., Zhang H., Zhang X., et al. Attenuation of SARS coronavirus by a short hairpin RNA expression plasmid targeting RNA-dependent RNA polymerase. Virology. 2004;324:84–89. doi: 10.1016/j.virol.2004.03.031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Matsumori A., Matoba Y., Sasayama S. Dilated cardiomyopathy associated with hepatitis C virus infection. Circulation. 1995;92:2519–2525. doi: 10.1161/01.cir.92.9.2519. [DOI] [PubMed] [Google Scholar]
  25. Matsumori A., Yutani C., Ikeda Y., Kawai S., Sasayama S. Hepatitis C virus from the hearts of patients with myocarditis and cardiomyopathy. Lab Invest. 2000;80:1137–1142. doi: 10.1038/labinvest.3780120. [DOI] [PubMed] [Google Scholar]
  26. Michel U., Malik I., Ebert S., Bahr M., Kugler S. Long-term in vivo and in vitro AAV-2-mediated RNA interference in rat retinal ganglion cells and cultured primary neurons. Biochem Biophys Res Commun. 2005;326:307–312. doi: 10.1016/j.bbrc.2004.11.029. [DOI] [PubMed] [Google Scholar]
  27. Murry C., Jerome K., Reichenbach D. Fatal parvovirus myocarditis in a 5-year-old girl. Hum Pathol. 2001;32:342–345. doi: 10.1053/hupa.2001.22743. [DOI] [PubMed] [Google Scholar]
  28. Nigro G., Bastianon V., Colloridi V., et al. Human parvovirus B19 infection in infancy associated with acute and chronic lymphocytic myocarditis and high cytokine levels: report of 3 cases and review. Clin Microbiol Infect. 2000;31:65–69. doi: 10.1086/313929. [DOI] [PubMed] [Google Scholar]
  29. Noutsias M., Fechner H., Jonge H., et al. Human coxsackie-adenovirusreceptor is co-localized with integrins avb3 and avb5 on the cardiomyocyte sarcolemma and upregulated in dilated cardiomyopathy — implications for cardiotropic viral infections. Circulation. 2001;104:275–280. doi: 10.1161/01.cir.104.3.275. [DOI] [PubMed] [Google Scholar]
  30. Opavsky M., Martino T., Rabinovitch M., et al. Enhanced ERK-1/2 activation in mice susceptible to coxsackievirus-induced myocarditis. J Clin Invest. 2002;109:1561–1569. doi: 10.1172/JCI200213971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Pauschinger M., Bowles N., Fuentes-Garcia J., et al. Detection of adenoviral genome in the myocardium of adult patients with idiopathic left ventricular dysfunction. Circulation. 1999;99:1348–1354. doi: 10.1161/01.cir.99.10.1348. [DOI] [PubMed] [Google Scholar]
  32. Pauschinger M., Doerner A., Kuehl U., et al. Enteroviral RNA replication in the myocardium of patients with left ventricular dysfunction and clinically suspected myocarditis. Circulation. 1999;99:889–895. doi: 10.1161/01.cir.99.7.889. [DOI] [PubMed] [Google Scholar]
  33. Ping Y.H., Chu C.Y., Cao H., Jacque J.M., Stevenson M., Rana T.M. Modulating HIV-1 replication by RNA interference directed against human transcription elongation factor SPT5. J Acquir Immune Defic Syndr Hum Retrovirol. 2004;1:46. doi: 10.1186/1742-4690-1-46. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Pinkenburg O., Platz J., Beisswenger C., Vogelmeier C., Bals R. Inhibition of NF-kappaB mediated inflammation by siRNA expressed by recombinant adeno-associated virus. J Virol Methods. 2004;120:119–122. doi: 10.1016/j.jviromet.2004.04.007. [DOI] [PubMed] [Google Scholar]
  35. Poller W, Kuhl U, Tschoepe C, Pauschinger M, Fechner H, Schultheiss HP (2005) Genome-environment interactions in the molecular pathogenesis of dilated cardiomyopathy. J Molec Med [Epub head of print 2 June 2005] [DOI] [PubMed]
  36. Rohayem J., Dinger J., Fischer R., Klingel K., Kandolf R., Rethwilm A. Fatal myocarditis associated with acute parvovirus B19 and herpesvirus 6 coinfection. J Clin Microbiol. 2001;39:4585–4587. doi: 10.1128/JCM.39.12.4585-4587.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Schubert S., Grunert H.-P., Zeichhardt H., Werk D., Erdmann V., Kurreck J. Maintaining inhibition: siRNA double expression vectors against coxsackieviral RNAs. J Mol Biol. 2005;346:457–465. doi: 10.1016/j.jmb.2004.11.074. [DOI] [PubMed] [Google Scholar]
  38. Stevenson M. Therapeutic potential of RNA interference. N Engl J Med. 2004;351:1772–1777. doi: 10.1056/NEJMra045004. [DOI] [PubMed] [Google Scholar]
  39. Takigawa Y., Nagano-Fujii M., Deng L., et al. Suppression of hepatitis C virus replicon by RNA interference directed against the NS3 and NS5B regions of the viral genome. Microbiol Immunol. 2004;48:591–598. doi: 10.1111/j.1348-0421.2004.tb03556.x. [DOI] [PubMed] [Google Scholar]
  40. Ulevitch R. Therapeutics targeting the innate immune system. Nat Rev Immunol. 2004;4:512–520. doi: 10.1038/nri1396. [DOI] [PubMed] [Google Scholar]
  41. Wang Z., Ren L., Zhao X., et al. Inhibition of severe acute respiratory syndrome virus replication by small interfering RNAs in mammalian cells. J Virol. 2004;78:7523–7527. doi: 10.1128/JVI.78.14.7523-7527.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Why H.J., Meany B.T., Richardson P.J., et al. Clinical and prognostic significance of detection of enteroviral RNA in the myocardium of patients with myocarditis or dilated cardiomyopathy. Circulation. 1994;89:2582–2589. doi: 10.1161/01.cir.89.6.2582. [DOI] [PubMed] [Google Scholar]
  43. Wiebusch L., Truss M., Hagemeier C. Inhibition of human cytomegalovirus replication by small interfering RNAs. J Gen Virol. 2004;85:179–184. doi: 10.1099/vir.0.19453-0. [DOI] [PubMed] [Google Scholar]
  44. Xia H., Mao Q., Eliason S.L., et al. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med. 2004;10:816–820. doi: 10.1038/nm1076. [DOI] [PubMed] [Google Scholar]
  45. Xiong D., Lee G.-H., Badorff C., et al. Dystrophin deficiency markedly increases enterovirus-induced cardiomyopathy: A genetic predisposition to viral heart disease. Nat Med. 2002;8:782–877. doi: 10.1038/nm737. [DOI] [PubMed] [Google Scholar]
  46. Yanagawa B., Spiller O.B., Choy J., et al. Coxsackievirus B3-associated myocardial pathology and viral load reduced by recombinant soluble human decay-accelerating factor in mice. Lab Invest. 2003;83:75–85. doi: 10.1097/01.lab.0000049349.56211.09. [DOI] [PubMed] [Google Scholar]
  47. Yanagawa B., Spiller O.B., Proctor D.G., et al. Soluble recombinant coxsackievirus and adenovirus receptor abrogates coxsackievirus b3-mediated pancreatitis and myocarditis in mice. J Infect Dis. 2004;189:1431–1439. doi: 10.1086/382598. [DOI] [PubMed] [Google Scholar]
  48. Yokoseki O., Suzuki J., Kitabayashi H., et al. cis Element decoy against nuclear factor-kappaB attenuates development of experimental autoimmune myocarditis in rats. Circ Res. 2001;89:899–906. doi: 10.1161/hh2201.099373. [DOI] [PubMed] [Google Scholar]
  49. Yoon J.S., Kim S.H., Shin M.C., et al. Inhibition of herpesvirus-6B RNA replication by short interference RNAs. J Biochem Mol Biol. 2004;37:383–385. doi: 10.5483/bmbrep.2004.37.3.383. [DOI] [PubMed] [Google Scholar]
  50. Zhang X.N., Xiong W., Wang J.D., Hu Y.W., Xiang L., Yuan Z.H. siRNAmediated inhibition of HBV replication and expression. World J Gastroenterol. 2004;10:2967–2971. doi: 10.3748/wjg.v10.i20.2967. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Zhou N., Fang J., Mukhtar M., Acheampong E., Pomerantz R.J. Inhibition of HIV-1 fusion with small interfering RNAs targeting the chemokine coreceptor CXCR4. Gene Ther. 2004;11:1703–1712. doi: 10.1038/sj.gt.3302339. [DOI] [PubMed] [Google Scholar]

Articles from Chronic Viral and Inflammatory Cardiomyopathy are provided here courtesy of Nature Publishing Group

RESOURCES